FGFR2 (R612T)
Sign in to save this workspaceFGFR2 · Variant type: point · HGVS: p.R612T
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Erdafitinib | 99.6% | 0.4% | 95.71 |
| 2 | Futibatinib | 99.3% | 0.7% | 98.48 |
| 3 | Infigratinib | 99.0% | 1.0% | 98.24 |
| 4 | Pemigatinib | 99.0% | 1.0% | 98.23 |
| 5 | Selpercatinib | 98.9% | 1.1% | 96.72 |
| 6 | Ponatinib | 98.8% | 1.2% | 78.23 |
| 7 | Alpelisib | 98.8% | 1.2% | 97.22 |
| 8 | Deucravacitinib | 97.8% | 2.2% | 98.99 |
| 9 | Nintedanib | 97.7% | 2.3% | 90.23 |
| 10 | Vandetanib | 97.2% | 2.8% | 95.74 |
| 11 | Axitinib | 96.1% | 3.9% | 93.23 |
| 12 | Pralsetinib | 95.2% | 4.8% | 93.43 |
| 13 | Tenalisib | 94.6% | 5.4% | 97.98 |
| 14 | Brigatinib | 92.6% | 7.4% | 82.96 |
| 15 | Repotrectinib | 92.1% | 7.9% | 84.21 |
| 16 | Pazopanib | 91.3% | 8.7% | 97.49 |
| 17 | Tivozanib | 90.8% | 9.2% | 92.42 |
| 18 | Ripretinib | 90.4% | 9.6% | 92.95 |
| 19 | Sunitinib | 89.6% | 10.4% | 91.73 |
| 20 | Canertinib | 87.0% | 13.0% | 96.49 |
| 21 | Entrectinib | 85.3% | 14.7% | 93.69 |
| 22 | Erlotinib | 84.3% | 15.7% | 99.75 |
| 23 | Lenvatinib | 83.8% | 16.2% | 97.74 |
| 24 | Tepotinib | 83.3% | 16.7% | 99.75 |
| 25 | Fedratinib | 82.8% | 17.2% | 96.21 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Erdafitinib | 99.6% | 99.0% | +0.6% |
| Futibatinib | 99.3% | 99.3% | +0.0% |
| Infigratinib | 99.0% | 98.8% | +0.2% |
| Pemigatinib | 99.0% | 98.7% | +0.2% |
| Selpercatinib | 98.9% | 95.0% | +3.9% |
| Ponatinib | 98.8% | 99.4% | -0.6% |
| Alpelisib | 98.8% | 98.9% | -0.1% |
| Deucravacitinib | 97.8% | 92.5% | +5.3% |
| Nintedanib | 97.7% | 97.0% | +0.8% |
| Vandetanib | 97.2% | 90.8% | +6.4% |
| Axitinib | 96.1% | 96.1% | -0.1% |
| Pralsetinib | 95.2% | 93.2% | +2.0% |
| Tenalisib | 94.6% | 96.0% | -1.3% |
| Brigatinib | 92.6% | 96.1% | -3.5% |
| Repotrectinib | 92.1% | 79.8% | +12.3% |
| Pazopanib | 91.3% | 88.9% | +2.4% |
| Tivozanib | 90.8% | — | — |
| Ripretinib | 90.4% | 85.4% | +5.0% |
| Sunitinib | 89.6% | — | — |
| Canertinib | 87.0% | — | — |
| Entrectinib | 85.3% | 81.5% | +3.7% |
| Erlotinib | 84.3% | — | — |
| Lenvatinib | 83.8% | 85.4% | -1.5% |
| Tepotinib | 83.3% | — | — |
| Fedratinib | 82.8% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| Lung Cancer | Lung | ref |
| carcinoma_lung | Lung | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 17.3ms